“…However, we should underline that: (I) in such trial patients with clinical metastases to para-aortic nodes were not eligible for randomization; as such, the survival benefit of D2 plus was denied when performed with a "prophylactic" intent, but a potential benefit in patients with distant node metastases could not be excluded; (II) several observational and phase II studies reported longterm survivors in patients with metastases to para-aortic nodes, when treated by D2 plus lymphadenectomy; these rates were particularly high when surgery is preceded by neoadjuvant chemotherapy (30-33); (III) the incidence of distant lymph node metastases in Western patients has been estimated to be higher than Asian series, because it is related, besides T stage, to proximal tumor location and diffuse Lauren histotype (34); (IV) the JCOG 9501 compared patients treated by D2 vs. D2 plus the dissection, but the surgical difference between the two groups was the removal of para-aortic nodes, whereas "posterior" stations (8p, 12b/p, 13) were similarly dissected in the two groups under study; as such, in our opinion the conclusions of the study do not justify the exclusion of "posterior" lymphadenectomy from surgical guidelines. For all these reasons, the GIRCG guidelines advice D2 plus lymphadenectomy in patients at risk of lymph node metastases to "posterior" and para-aortic nodes (17). These can be identified in advanced forms located in proximal third, and advanced diffuse histotype in the distal third for para-aortic lymphadenectomy; the results of an observational GIRCG study for the identification of groups at risk of metastases to "posterior" stations are going to be published.…”